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Abstract
Background: Merkel cell carcinoma (MCC) is an unusual primary neuroendocrine carcinoma of
the skin. MCC is a fatal disease, and patients have a poor chance of survival. Moreover, MCC lacks
distinguishing clinical features, and thus by the time the diagnosis is made, the tumour usually have
metastasized. MCC mainly affects sun-exposed areas of elderly persons. Half of the tumours are
located in the head and neck region.
Methods: MCC was first described in 1972. Since then, most of the cases reported, have been in
small series of patients. Most of the reports concern single cases or epidemiological studies. The
present study reviews the world literature on MCC. The purpose of this article is to shed light on
this unknown neuroendocrine carcinoma and provide the latest information on prognostic markers
and treatment options.
Results: The epidemiological studies have revealed that large tumour size, male sex, truncal site,
nodal/distant disease at presentation, and duration of disease before presentation, are poor
prognostic factors. The recommended initial treatment is extensive local excision. Adjuvant
radiation therapy has recently been shown to improve survival. Thus far, no chemotherapy
protocol have achieved the same objective.
Conclusion: Although rare, the fatality of this malignancy makes is important to understand the
etiology and pathophysiology. During the last few years, the research on MCC has produced
prognostic markers, which can be translated into clinical patient care.
Background
The Merkel cell
The Merkel cell (MC) was first described by the German
histopathologist Friedrich Sigmund Merkel in his classic
article published in 1875: Merkel F: "Tastzellen und
Tastkörperchen bei den Haustieren und beim Menschen"
[1]. He demonstrated the existence of touch cells in the
snout skin of pigs, calling them "Tastzellen" because of
their putative function in the touch sensation. Merkel pos-
tulated that the cells acted as mechanoreceptors in all ani-
mals.
Distribution of Merkel cells
MCs are normal constituents of the basal layer of the epi-
dermis and the follicular epithelium [2] (Figure 1). They
are scarce in normal skin, but are present in high numbers
and form clusters in areas of sensory perception. In close
association with primary nerve endings in the skin, they
form the MC-axon complex.
On light microscopy, MCs are large, oval, amphophilic,
clear cells situated in the basal or suprabasal layer of the
epidermis. They are not easily distinguished from other
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nonkeratinocytic epidermal cells, e.g. melanocytes and
Langerhans cells, by light microscopic immunohisto-
chemistry. Special techniques such as immunohistochem-
istry, electron microscopy or transmission electron
microscopy are therefore required for their identification.
Function in developing embryo and adult
In human development, MCs can be detected in the epi-
dermis in the 8th gestational week [3]. In the developing
embryo, MCs are thought to be involved in the formation
of the subepidermal nerve plexus [4,5], and in the forma-
tion and proliferation of eccrine sweat glands and hair fol-
licles [6]. In the adult MCs are thought to act as slow
acting type-I mechanoreceptors. Together with sensory
nerve endings, they form MC-axon complexes that are
activated by steady skin indentation [7]. The function of
MCs in this complex is, however, enigmatic. Two possible
functions have been proposed: either they may act as
attracters of developing or regenerating type I nerve fibres
[8] or they may have neuromodulatory or neuroregula-
tory functions in the basal epidermis, such as keratinocyte
proliferation stimulation, maintenance of the differentia-
tion of keratinocytes, or the release of bioactive substances
to subepidermal structures [9].
Origin of the Merkel cell
The origin of the MC is still controversial. The cell may
derive either from the epithelial cells of the epidermis or
from the neural crest migrating to the epidermis during
embryogenesis. In the 1980s and 1990s, the epidermal
origin from keratinocytes with an aberrant differentiation
[10] was the prevailing hypothesis [3,11-13], as suggested
by the epidermal location of the MC, the expression of
cytokeratins and the results of skin transplantation exper-
iments [14,15]. Recent studies, however, have provided
strong evidence in support of the neural crest origin
[16,17].
Merkel cell carcinoma
The Merkel cell carcinoma (MCC) was first described in
1972, when Toker presented the first five cases under the
name "trabecular carcinoma of the skin", assuming them
to represent an eccrine, sweat gland-derived carcinoma
[18]. In electron microscopic (EM) studies, Tang and
Toker later identified dense-core neuroendocrine granules
within the tumour cells, thus demonstrating their origin
from MCs [19].
The "cell of origin" of MCC is, however, still speculative.
There are morphological and biological similarities
between the MC and MCC. The common presence of neu-
roendocrine granules [20] and the positive immunostain-
ing for cytokeratin-20 (CK-20), for instance, provide
evidence for MC origin [21], although this may indicate
differentiation rather than origin. However, certain differ-
ences also exist between the MC and MCC, such as the
fibrous whorls and neurofilaments that are seen in MCC
but not in normal MCs. Another argument against the MC
as the cell of origin for MCC is that mitoses have not been
detected in human MCs [3,22]. There is a contradiction
between the location of the cell in the skin in MCs and in
MCC, the tumour practically always involves the dermis,
sparing the epidermal structures.
Toker called the first five cases of MCC "trabecular carci-
noma of the skin." This name derived from the trabecular
architecture of the tumour, which is the most characteris-
tic, but the uncommon, configuration of three histologi-
cal patterns. Over the years, the name of this tumour has
been the subject of lively discussion. Several names and
synonyms have been proposed; either based on histolog-
ical features or derived from the term "Merkel cell". These
include derivatives such as "Malignant Merkel-cell
tumour" [23], "Merkel cell tumour" [24] or "Merkel cell
tumour of the skin" [25]. It was not until the mid 1980s
that the term "Merkel cell carcinoma" was established. In
the year 1980, Johannessen and co-workers seem to have
used this term for the first time [26]. The term "Primary
neuroendocrine carcinoma of the skin" was coined to
reflect the pathophysiology of the disease.
Solitary Merkel cells in the normal skin, expressing cytokera- tin-20 Figure 1
Solitary Merkel cells in the normal skin, expressing cytokera-
tin-20.World Journal of Surgical Oncology 2006, 4:7 http://www.wjso.com/content/4/1/7
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Histology
The histology of MCC is typical of small round blue cell
tumours, an entity that includes a wide variety of highly
malignant tumours: the Ewing family of tumours, olfac-
tory neuroblastoma (esthesioblastoma), rhabdomyosar-
coma, neuroblastoma, lymphoma, desmoplastic small
cell tumour, osteosarcoma, small cell lung carcinoma
(SCLC), small cell melanoma and mesenchymal chondro-
sarcoma [27,28].
Histologically, MCC can be classified into three distinct
subtypes [29-31]. In haematoxylin-eosin staining, typical
histology of the MCC is small blue cells with sparse cyto-
plasm. Nuclei are medium-sized. Mitoses are abundantly
and the tumour expands frequently to subcutaneous tis-
sue. Chromatin is displayed in typical salt and pepper pat-
tern.
The classification to the subtypes is usually reserved for
the anatomical studies. The first of these is the trabecular
subtype, described originally by Toker[18]. This is the
least frequent histological pattern. Cells are arranged in
distinctly organoid clusters and trabeculae with occa-
sional ribbons. This type of tumour usually occurs adja-
cent to adnexal structures, particularly hair follicles.
The intermediate subtype is the most frequent histologi-
cal subtype [32]. It exhibits a solid and diffuse growth pat-
tern. Cells are less compactly arranged, and the cytoplasm
is less abundant than in the trabecular type. Mitoses and
focal areas of necrosis are frequent. These tumours usually
arise adjacent to adnexa, but may invade the epidermis.
The clinical behaviour is more aggressive than that of
tumours of the trabecular type. The small cell type mim-
ics small cell tumours of other sites, e.g. SCLC [33]. The
tumours arise in the dermis and appear as solid sheets and
clusters of cells. The clinical behaviour of this subtype
appears to be as similar as the small cell tumours of other
origins.
Diagnosis
Diagnosis is based on typical histology representation on
haematoxylin-eosin -stained slides together with the
results of immunohistochemistry [32]. A typical histolog-
ical finding in MCC is the presence of tumour tissue
within the dermis with repeated extensions to underlying
subcutaneous tissue (Figure 2). The epidermis, papillary
dermis and adnexal structures are not usually involved.
Cytological features include sparse cytoplasm with uni-
form, monotonous medium-sized nuclei and abundant
mitoses [34]. All these cytomorphological features can be
present as well in fine needle aspirates [35]. EM studies
show that the ultrastructure of neuroendocrine granules
of the tumour is similar to that of normal MCs. The most
consistent findings are the aggregation of intermediate fil-
aments in a paranuclear location and the existence of
membrane-bound dense core granules. Only 10 % of all
MCC tumours are intraepidermal [36].
Immunohistochemistry – differentiation
The tumour expresses both epithelial and neuroendocrine
markers, and thus exhibits both epithelial and neuroen-
docrine differentiation.
Epithelial differentiation
Of the intermediate filaments, MCC expresses low-molec-
ular-weight cytokeratins (keratins 8,18,19 and 20), the
simple epithelial type being the most marked [20,37]. The
most important keratin in differential diagnostics is cytok-
eratin-20 (CK-20). CK-20 is a low-molecular-weight
cytokeratin, in normal tissues it is only expressed in the
gastrointestinal epithelium, urothelium, and MCs [38]. It
has been shown that CK-20-positivity in MCC serves to
distinguish it from pulmonary small cell carcinoma. Con-
sidered a sensitive and specific marker for MCC, CK-20 is
helpful in efforts to distinguish between MCC and other
malignant neoplasms, since it is not usually expressed in
neuroendocrine carcinomas of other sites, such as SCLC
[39,40] (Figure 2). Although up to 30 % of metastatic neu-
roendocrine carcinoma from lung might stain for CK-20,
but they always stain for TTF-1, which is negative in MCC
[41]. In some 5 – 25% of MCC cases, CK-20 is negative
[42,43].
Tissue-specific transcription factors control cell determi-
nation and differentiation. Thyroid transcription factor 1
(TTF-1) is a tissue specific transcription factor expressed in
epithelial cells of the thyroid and lung, as well as in certain
areas of the brain [44]. TTF-1 is employed to differentiate
between MCC and small-cell tumours [45,46], MCC is
negative for TTF-1 [47] (Figure 2).
Combining TTF-1 with CK-20 provides a sound basis for
diagnosis. Most adenocarcinomas from other sites
(breast, lung, endometrium) and neuroendocrine carci-
nomas such as SCLC are essentially negative for CK-20
[40] while most are negative for CK-20, those from the
lung are postitive for TTF-1. Table 1 presents the immuno-
histochemistry for the differentiation diagnosis of MCC.
Neuroendocrine differentiation
Due to neuroendocrine differentiation, MCC always
stains positively for neuron-specific enolase (NSE), which
is a general marker of neuroendocrine tumours [48-50].
CD56, or neural cell adhesion molecule (NCAM), has
recently been demonstrated to be a neuroendocrine
marker of the pulmonary neuroendocrine cell system as
well as MCC [51,52]. Although, McNiff and co-workers
recently reminded of the pitfalls in using CD56 marker for
MCC diagnosis [53] Chromogranin A (CrA), a member ofWorld Journal of Surgical Oncology 2006, 4:7 http://www.wjso.com/content/4/1/7
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the chromogranin family, is a major protein that accounts
for a large amount of the soluble matrix of neurosecretory
granules. First isolated from chromaffin cells of the adre-
nal medulla, CrA is the most widely distributed marker of
endocrine tumours [54]. MCC shows a focal, positive
immunoreaction to CrA [55,56] (Figure 2). Synapto-
physin is a transmembrane channel protein of small pres-
ynaptic vesicles. It is expressed in neuroendocrine and
neural cells and diffusely in neuroendocrine system cells
[57,58]. Both primary and metastatic neuroendocrine car-
cinomas are habitually synaptophysin positive [59,60].
MCC consistently shows positive immunoreactions to
synaptophysin [56,61] (Figure 2).
Newer markers of neuroendocrine differentiation intro-
duced for MCC are the microtubule-associated proteins
(MAPs). These are the major component of the cytoskele-
ton family of proteins associated with the microtubule
assembly of the central and peripheral nervous system
[62,63]. Specific MAPs have been identified in specific cell
types. MAP-2, for instance, is a highly sensitive and spe-
cific marker of neuroendocrine differentiation [62-64].
Liu et al, demonstrated MAP-2 expression in all MCC sam-
ples, even though CK-20 staining was negative [65]. In
general, MCC shows a high degree of neuroendocrine dif-
ferentiation. A higher expression of CrA and synapto-
physin associated with more indolent behaviour [56].
DNA copy number changes
Different types of chromosomal irregularities have been
documented in MCC tumours and cell lines [66-68]. The
most common aberrations engage chromosomes 1, 6, 11
and 13. Trisomy of chromosome 6 is a widely considered
as recurrent aberration [69,70]. Trisomy of chromosome
1 appears to be typical of MCC [71]. In the chromosome
11 a partial trisomy has been documented [72] as well as
complete trisomy [73]. In chromosome 13 loss was recog-
nizable [72] in addition to LOH [74]. So far it seems that
high-copy number amplifications for chromosomal sub-
regions are a rare event in MCC [75]. Although DNA copy
number changes have not been established as prognostic
factor for MCC, primary tumours expressing DNA altera-
tions were predominantly distinguished in large sized
tumours, and risk of metastatic dissemination was three-
fold compared to tumours with no DNA alterations [76].
Clinical presentation and staging
The clinical presentation of this tumour is rather non-spe-
cific. MCC is usually, at least at early stages of the disease,
defined as a small painless erythematous intradermal
mass, usually with no ulceration [77,78]. Especially small
tumours in particular can appear somewhat benign,
whereas large tumours have an unquestionably malignant
appearance. Because of the rare nature of this neoplasm, it
is often mistaken for more common skin tumours of epi-
thelial origin. Most common presumptive clinical diagno-
sis is cyst.
There is no classification scheme for MCC such as there is
for most carcinomas or sarcomas. At present, staging of
most malignant tumours is based on the T(umour)
N(odes) M(etastasis) classification (TNM classification of
malignant tumours – 6th edition, 2002). Concerning the
skin malignancies the TNM classification applies to carci-
nomas of the skin in general and malignant melanoma. In
most published series MCC is not classified according to
the TNM system.
Yiengpruksawan has, however, proposed a staging system
that has been widely recognised in the treatment of MCC
[77], which is presented in Table 2.
Incidence and clinical behaviour of MCC
The reported annual incidence of MCC ranges from 0.2 to
0.45 per 100 000 [79,80]. Incidence has tripled since
1986:1986 0.15 per 100,000 and 2001 0.44 per 100,000
[81]. It is 100 times as rare as melanoma [82]. MCC is
principally a disease of the Caucasian race. The annual
age-adjusted incidence of MCC is 0.23 per 100,000 for
whites and 0.01 for blacks [83]. The literature contains
only single case reports of black Africans or African-Amer-
icans with MCC [84-86]. Both sexes are affected, though
earlier studies showed a slight male predominance [87-
89]. The number of reported patient series is, however
growing, and recent investigations have shown an equal
distribution of the sexes or even a minor female preva-
lence [90-92]. MCC mainly affects the elderly, the mean
age at presentation being about 75 years [93,94]. Age-spe-
cific incidence was highest in the elderly, 4.28 per 100,000
in the 85+ age group [81] Only a few cases occur before
the age of 50, and is usually related to immunosuppres-
sion [95].
MCC usually occurs in sun-damaged skin. The tumours
are often found in close proximity to other lesions of
actinically damaged skin, for instance, in cases of Bowen
disease, squamous cell carcinoma, basal cell carcinoma,
solar keratosis and lentigo maligna. The most common
site is the head and neck region [96]. Pathogenetic factors
such as UV irradiation may contribute to tumour develop-
ment [68,97]. Miller and Rabkin have calculated that the
incidence of MCC rises along with an increase in potential
exposure to solar UVB. They found statistical significance
between the incidence of MCC and UVB exposure [83].
The natural history of MCC is variable and dependent on
the stage of disease at presentation [98]. Typically MCC
has a tendency to progress rapidly, and in just a few
months, the tumour may attain a large diameter. There-
fore, early diagnosis and surgery are strongly advocated.World Journal of Surgical Oncology 2006, 4:7 http://www.wjso.com/content/4/1/7
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Several studies established a close correlation between
overall survival and tumour size. The overall survival rate
is largely influenced by tumour size (≥ 2 cm) [99,100]. In
some studies dense lymphocytic infiltrates have been
associated with poor prognosis [101].
The typical clinical course of the disease is rapid progres-
sion of the primary tumour with early and frequent metas-
tasis to the regional lymph nodes. The sentinel lymph
node biopsy (SLNB) technique has provided information
on the metastatic dissemination at the presentation. In a
meta-analysis of 60 MCC patients, Mehrany and co-work-
ers detected 33% of the patients having metastatic dissem-
ination in the sentinel lymph node at the presentation
[102]. Then again, Hohaus and co-workers in their 17
patients retrospective analysis reported only 3 (18%) of
the patients at stage II at the presentation [103]. Allen and
co-workers detected 5/26 (19%) of the patients having
positive lymph nodes at the presentation [104].
Recurrences are frequent. Allen et al, at the Memorial
Sloan-Kettering Cancer Center's identified 251 patients
who had been treated between 1970 and 2002. The
median time to recurrence was 9 months, and 102
patients (43%) recurred [98]. Primary site on the lower
limb had an adverse effect on locoregional recurrencies
[105].
Although the natural course of MCC is usually defined
with metastatic spread, there are some reports in the liter-
ature (10 cases) of spontaneous regression [106,107].
Mori and co-workers have studied the apoptosis in eight
cases of MCC [108] and found high apoptotic rate in MCC
samples. Inoue et al have examined the mechanisms
behind the spontaneous regression in seven MCC samples
[109]. The TUNEL index and number of lymphocytes
around the tumour nests was increased in the samples
with spontaneous regression, furthermore the majority of
the infiltrating lymphocytes were T-cells [109]. They con-
cluded that apoptosis and local T-cell mediated immune
response might be involved in spontaneous regression of
MCC.
Co-existing malignancies
MCC has been associated with other skin tumours (squa-
mous cell carcinoma, basal cell carcinoma) and haemato-
logical (B-cell) malignancies [110-112]. In addition,
adenocarcinomas of the breast and ovaries have been
shown to have an association with MCC. Co-malignan-
cies, whether they appear before, after or simultaneously
with MCC, are associated with higher MCC-specific mor-
tality [113,114].
Immunosuppression: therapeutic and acquired
The incidence of MCC is abnormally high (8%) among
immunosuppressed patients. Such patients are moreover
younger, 49% being under the age of 50 [115,116]. Weak-
ened immunity increases the risk of MCC; HIV patients,
for example, have a 13.4 times increased risk of acquiring
MCC [117].
Prognosis
The prognosis is rather poor. The 2-year survival rate is 30
– 50% [118,119], Kokoska included 35 and Linjawi 10
patients in his study. Agelli and Clegg have studied the
epidemiology of MCC in the United States in a patient
population of 1034 by using Surveillance, Epidemiology,
and End Results Program. The 5-year survival rate in their
study was 75%, 59% and 25% for localised, regional and
distant MCC, respectively [120]. Overall survival (OS) is
associated with the stage of disease at presentation.
Female sex, localized disease, and younger age were posi-
tive predictors of survival [78,120,121]. The risk of recur-
rence or metastasis was 19 times as great in sentinel node
biopsy-positive patients as in biopsy-negative patients (p
= 0.005) [102].
Local recurrences are frequent, occurring in up to 44% of
patients [30,88,93]. There have been some reports of
lymph node metastasis alone, with no detectable primary
Immunohistochemical staining of primary Merkel cell carci- noma for differential diagnosis and neuroendocrine differenti- ation Figure 2
Immunohistochemical staining of primary Merkel cell carci-
noma for differential diagnosis and neuroendocrine differenti-
ation. A. Hematoxylin-eosin staining, the tumour cells have 
round nuclei, original magnification 200×. B. Positive cytoker-
atin-20 staining, showing typical punctate pattern of immu-
nostaining, original magnification 400×. C. Negative staining 
for Thyroid-transcriptor factor-1, original magnification 
400×. D. chromogranin -A staining, original magnification 
400× and E. synaptophysin staining, original magnification 
400×.World Journal of Surgical Oncology 2006, 4:7 http://www.wjso.com/content/4/1/7
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tumour [122,123]. Depending on the length of the fol-
low-up period up to 36% of the patients develop regional
lymph node metastasis [124]. Distant dissemination is
not infrequent, up to 40–50% of patients developing vis-
ceral metastasis [125-127], particularly to the lungs, liver
and bone [128,129].
Surgical treatment
Because of the rarity of the tumour, there is multitude of
treatment protocols. However, the surgical treatment
seems to be the corner stone of the different treatment
protocols.
Early, radical surgery is the recommended procedure for
the treatment of primary MCC [92,130]. Margins of 2 – 5
cm are recommended for better local control. Neverthe-
less, consensus on the width of margins has not yet been
reached. Yiengpruksawan and co-workers, O'Connor and
Brodland reported better local control with margins of > 3
cm [77,131]. Then again, there have been reports that
larger free margins confer no advantage on survival [124].
Gillenwater and co-workers had sixty-six head and neck
MCC cases included in their study, but only eighteen
patient's data was sufficient for the statistical analysis.
They state themselves that the small patient population in
their study might explain this result. Because lymph node
metastases develop in approximately 50% of patients in
the course of the disease, some authors recommend pro-
phylactic lymphadenectomy in all patients [97,118]. Then
again, the patient materials are small: Lawenda had nine
patient study population and Kokoska 35. Silva and co-
workers recommend lymphadenectomy for tumours with
10 or more mitoses per high-power field, in cases of lym-
phatic invasion, or when tumours are composed of small
cells, that is, the small-cell subtype [132].
According to the literature on MCC, the sentinel lymphn-
ode biopsy (SLNB) technique was used in approximately
100 cases between 1976 and 2002. Most reports advocate
SLNB because morbidity is low, and because it provides
an easy and reliable way of locating occult metastasis
[102,133,134]. Recent studies have investigated the effi-
cacy of SLNB in helping to determine whether lymph
basin evacuation is necessary. These studies have been
conducted on only a small series of patients, but even so,
the results suggest that a negative sentinel node may obvi-
ate the need for neck dissection. SLNB is strongly advo-
cated in the treatment and staging of individual tumours.
Its use will improve the accrual of patients to adjuvant and
further surgical treatment protocols [102,135]. Especially
for the MCC cases occurring in the head and neck region
the SLNB seems to be a safe and reliable technique for
regional staging [136].
It is widely accepted that patients with regional node
metastases or local or regional recurrence should undergo
excision of the primary lesion and lymph node dissection
[130]. Adjuvant radiation therapy to the primary site and
regional nodes is generally recommended in addition to
lymph node dissection. Tumours arising in the head and
neck region with parotid gland metastasis seem to have
even poorer prognosis [137]. As a result elective lymph
node dissection has been recommended for younger
patients with large tumours or tumours of the head and
neck region [138-140].
Mohs micrographic surgery is a surgical technique devel-
oped by Frederick Mohs in the 1930s at the university of
Wisconsin [141]. Briefly, the technique consists of
debulking the tumour with a semisharp curette, in order
to outline the skin tumour. Subsequently, a scalpel is used
to remove the tissue in a horizontal fashion with 2 mm
clinical margins. The tissue sample is taken to the labora-
tory for the processing. The patient is bandaged and wait-
ing for the microscopic results. The horizontal frozen
sections are cut from the undersurface of the tissue paral-
lel to the skin surface, rather than vertically. This method
allows for microscopic examination of the entire deep and
peripheral margins of the surgical specimen. The surgeon
does the microscopic examination. These steps are then
repeated until the margins are free from the tumour, and
the defect is closed.
Mohs micrographic surgery has been recommended as an
advanced technique for local control, especially in areas
calling for excellent cosmetic results (i.e. head and neck
Table 1: Immunohistochemical markers in the differential diagnosis of MCC.
CK-20 TTF-1 NSE S-100 GrA SYP NFP CD56 MAP-2 LCA
MCC +- + - + / - + / - + ++ -
SCLC - + +/- - -/+ + -/+ + + -
MM -- - + - - + -
LGNEC ++ + + - / +
Malignant lymphoma -- - - - - / + +
+ positive, +/- mostly positive, -/+ mostly negative, - negative. CK-20 cytokeratin 20, TTF-1 thyroid transcription factor 1, NSE neuron-spesific 
enolase, GrA gromogranin A, NFP neurofilament proteins, CD56 neural adhesion molecule, MAP-2 microtubule associated protein 2, LCA 
leukocyte common antigen SCLC small cell lung carcinoma, MM malignant melanoma, LGNEC low grade neuroendocrine carcinomasWorld Journal of Surgical Oncology 2006, 4:7 http://www.wjso.com/content/4/1/7
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region) without compromising the principles of cancer
surgery [142,143]. Then again, Brissett and co-workers
reported inferior 2-year survival with patients undergoing
Mohs micrographic surgery compared to patients who
had wide local excision alone or wide local excision and
lymphnode basin evacuation, 33%, 68% and 100%
respectively [130].
Oncological treatment
Chemotherapy is generally reserved for stage III (distant
metastasis) cases of MCC. The carcinoma has often been
shown to respond to chemotherapy but, as in SCLC,
remission is brief. Recently, Waldman and co-workers
reported a complete remission that lasted for 6 months.
The remission was achieved through the use of high-dose
polychemotherapy following autologous blood stem cell
transplantation [144]. Some months previously, Voog et
al reported similar results, the rates of response to second-
line (n = 33) and third-line (n = 10) chemotherapy being
45% and 20%, respectively [145]. No chemotherapeutic
protocol has, however, been able to achieve a significant
increase in survival rate [105].
No standard chemotherapy protocol has yet been estab-
lished for the treatment of MCC. Because of the morpho-
logical and immunohistochemical similarity of MCC to
SCLC, chemotherapy has been performed with protocols
based largely on agents active in SCLC. A wide variety of
chemotherapeutic agents, including the cytostatic drugs
cyclophosphamide, doxorubicin, epirubicin, vincristine,
etoposide, cisplatine, carboplastin, 5-fluorouracil, dacar-
bazine, mitoxantrone, bleomycine and iphosphamide,
have been discussed [87,96,145-147]. Unfortunately,
reports to date consist of only small studies and anecdotal
evidence. A few reports have shown markedly high mor-
tality among MCC patients receiving chemotherapy for
metastatic disease. Tai and co-workers reported seven
(3.4%) toxic deaths among 204 cases [96]. Voog and co-
workers gave even higher mortality, the rate of toxic death
during first-line treatment being 7.7% in 101 patients
[145].
MCC is a highly radiosensitive tumour, which has been
demonstrated in in vitro studies [148]. Many authors have
recommended post-operative radiotherapy based on the
retrospective comparison of patients treated with surgery
alone with patients treated with surgery and post-opera-
tive radiotherapy [149,150]. In a recent series of 37 MCC
patients Veness et al. reported a significantly longer
median disease free survival with patients treated with
surgery and adjuvant radiotherapy and than those under-
going surgery alone (23 months vs. 6 months) [151].
Moreover, outcome improved markedly in patients
receiving adjuvant radiotherapy after surgery [152]. Radi-
ation is most commonly used as an adjuvant therapy after
surgery but it may be used to as the only treatment espe-
cially in patients who are too weak to undergo surgical
treatments [153,154]
Conclusion
Recent advances in the research of MCC have revealed fea-
tures in the natural biology of this malignancy. However,
several questions regarding the biology and pathology of
the tumour remain to be addressed. The molecular events
leading to oncogenic alterations must be identified. Mech-
anisms of metastasis are still largely concealed. Revealing
these biological properties, hopefully, will lead to discov-
ery of new treatments, e.g. the role of anti-angiogenic
medication is still uncertain. Of the surgical treatments,
the sentinel lymph node biopsy has proven its efficacy in
finding the clinically occult metastasis and accrual of
patients to adjuvant and further surgical and oncological
treatment protocols.
Several markers for prognosis have been studied, but none
have proven its value like large, ≥ 2 cm, primary tumour
size. The wide range of the factors associated to survival
may reflect the absence of large institutional studies.
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